610 related articles for article (PubMed ID: 34480725)
1. Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?
Vu M; Smith KJ; Aspinall SL; Clancy CJ; Buehrle DJ
Clin Drug Investig; 2021 Oct; 41(10):885-894. PubMed ID: 34480725
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
3. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
Bounthavong M; Hsu DI; Okamoto MP
Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.
Kufel WD; Parsels KA; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ
Pharmacotherapy; 2023 Jan; 43(1):15-23. PubMed ID: 36371648
[TBL] [Abstract][Full Text] [Related]
6. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
10. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
11. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
Rio-Marques L; Hartke A; Bizzini A
Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
[TBL] [Abstract][Full Text] [Related]
13. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
14. Comparing the pharmacokinetics and organ/tissue distribution of anti-methicillin-resistant
Kobuchi S; Kanda N; Okumi T; Kano Y; Tachi H; Ito Y; Sakaeda T
Xenobiotica; 2022 Jun; 52(6):583-590. PubMed ID: 35815433
[TBL] [Abstract][Full Text] [Related]
15. Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections.
Yeager SD; Oliver JE; Shorman MA; Wright LR; Veve MP
Int J Antimicrob Agents; 2021 May; 57(5):106329. PubMed ID: 33785363
[TBL] [Abstract][Full Text] [Related]
16. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
[TBL] [Abstract][Full Text] [Related]
17. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant
Wei X; Zhao M; Xiao X
J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
19. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]